<div id="readability-page-1"><p>Allogene Therapeutics, Inc. (NASDAQ:ALLO - Get Free Report) rose 10.3% on Tuesday . The company traded as high as $2.29 and last traded at $2.2950. Approximately 5,363,671 shares were traded  during trading, a decline of 10% from the average daily volume of 5,955,742 shares. The stock had previously closed at $2.08.</p><div><p><span></span><span>Get <strong>Allogene Therapeutics</strong> alerts:</span></p></div><h2>Analyst Ratings Changes</h2><ul><li>3 Stocks With Sky-High Short Interest Levels</li></ul><p>A number of research firms have recently weighed in on ALLO. UBS Group started coverage on shares of Allogene Therapeutics in a research report on Wednesday, January 7th. They set a &#34;buy&#34; rating and a $8.00 price target for the company. Citizens Jmp raised shares of Allogene Therapeutics from a &#34;market perform&#34; rating to an &#34;outperform&#34; rating and set a $5.00 price objective for the company in a report on Friday, January 9th. Citigroup raised shares of Allogene Therapeutics from a &#34;market perform&#34; rating to an &#34;outperform&#34; rating in a research report on Friday, January 9th. Finally, Wall Street Zen raised shares of Allogene Therapeutics from a &#34;sell&#34; rating to a &#34;hold&#34; rating in a research report on Sunday. Ten equities research analysts have rated the stock with a Buy rating and two have given a Sell rating to the stock. According to data from MarketBeat.com, the company  has a consensus rating of &#34;Moderate Buy&#34; and an average price target of $8.40.</p><p><b>View Our Latest Stock Report on ALLO</b></p><h2>Allogene Therapeutics Trading Up 10.3%</h2><ul><li>2 Downgrades in Healthcare You Might Want to Buy</li></ul><p>The firm has a market cap of $515.76 million, a P/E ratio of -2.34 and a beta of 0.60. The business's 50-day moving average is $1.62 and its two-hundred day moving average is $1.37. </p><h2>Insider Buying and Selling</h2><p>In other Allogene Therapeutics news, EVP Zachary Roberts sold 35,700 shares of the firm's stock in a transaction on Monday, February 2nd. The stock was sold at an average price of $1.77, for a total value of $63,189.00. Following the sale, the executive vice president directly owned 581,166 shares in the company, valued at approximately $1,028,663.82. This trade represents a 5.79% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, CEO David D. Chang sold 95,269 shares of the business's stock in a transaction on Monday, February 2nd. The shares were sold at an average price of $1.80, for a total transaction of $171,484.20. Following the transaction, the chief executive officer directly owned 5,185,862 shares of the company's stock, valued at approximately $9,334,551.60. This trade represents a 1.80% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last 90 days, insiders sold 215,855 shares of company stock worth $378,426. Company insiders own  13.20% of the company's stock. </p><h2>Institutional Investors Weigh In On Allogene Therapeutics</h2><p>Institutional investors and hedge funds have recently modified their holdings of the stock. Mercer Global Advisors Inc. ADV boosted its position in shares of  Allogene Therapeutics by 23.0% in the 4th quarter. Mercer Global Advisors Inc. ADV now owns 29,512 shares of the company's stock valued at $40,000 after purchasing an additional 5,514 shares during the period.  CANADA LIFE ASSURANCE Co lifted its stake in  Allogene Therapeutics by 27.3% during the third quarter. CANADA LIFE ASSURANCE Co now owns 39,730 shares of the company's stock valued at $50,000 after buying an additional 8,519 shares in the last quarter.  Quadrature Capital Ltd boosted its holdings in shares of  Allogene Therapeutics by 29.6% in the second quarter. Quadrature Capital Ltd now owns 44,050 shares of the company's stock worth $50,000 after buying an additional 10,059 shares during the period.  Brighton Jones LLC increased its position in shares of  Allogene Therapeutics by 81.6% in the third quarter. Brighton Jones LLC now owns 25,168 shares of the company's stock worth $31,000 after acquiring an additional 11,311 shares in the last quarter.  Finally, Zacks Investment Management raised its holdings in shares of  Allogene Therapeutics by 2.7% during the third quarter. Zacks Investment Management now owns 526,132 shares of the company's stock valued at $652,000 after acquiring an additional 13,831 shares during the period. Institutional investors and hedge funds own  83.63% of the company's stock. </p><h2>Allogene Therapeutics Company Profile</h2> (Get Free Report)<p>Allogene Therapeutics is a clinical-stage biotechnology company focused on developing allogeneic, or “off-the-shelf,” chimeric antigen receptor T-cell (CAR T) therapies to treat a range of hematologic malignancies and solid tumors. The company leverages gene-editing technologies to generate universally compatible engineered T cells, aiming to overcome the limitations of patient-specific CAR T approaches such as manufacturing delays, variable product quality and treatment resistance.  </p><p>The company's pipeline includes multiple allogeneic CAR T candidates targeting key antigens in blood cancers.</p><h2>Read More</h2><ul><li>Five stocks we like better than Allogene Therapeutics</li><li>The Foundation Behind Today's Biggest Tech Trends</li><li>Unlocked: Elon Musk’s Next Big IPO</li><li>How a Family Trust May Be Able To Help Preserve Your Wealth</li><li>This makes me furious</li><li>The free stock picks nobody’s talking about</li></ul><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in Allogene Therapeutics Right Now?</h2><p>Before you consider Allogene Therapeutics, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Allogene Therapeutics wasn't on the list.</p><p>While Allogene Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

ALLO

SBIO

IBBQ

<p>Allogene Therapeutics (NASDAQ:ALLO) shares rose 10.3% to $2.2950, with 5.36 million shares traded. Analysts have given a consensus rating of "Moderate Buy" with an average price target of $8.40. Recent insider sales included EVP Zachary Roberts and CEO David D. Chang. Institutional investors hold 83.63% of the stock. Allogene focuses on developing allogeneic CAR T therapies for hematologic malignancies and solid tumors, leveraging gene-editing technologies.</p>

Allogene Therapeutics (NASDAQ:ALLO) Shares Up 10.3% - Should You Buy?